WCM
BSTC

Wedge Capital Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Wedge Capital Management’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-27,373
Closed -$1.47M – 603
2019
Q3 		$1.47M Hold
27,373
– – 0.02% 292
2019
Q2 		$1.63M Buy
+27,373
New +$1.72M 0.02% 292
2017
Q2 		– Sell
-38,200
Closed -$2.09M – 590
2017
Q1 		$2.09M Buy
+38,200
New +$2.02M 0.02% 263

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wedge Capital Management's BSTC Position: Q4 2019 in Review

Wedge Capital Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2019, closing a stake of 27,373 shares — an estimated $1.47M sold.

Wedge Capital Management first reported a position in BSTC in Q1 2017 and held it in 3 quarters. The position peaked at $2.09M in Q1 2017. 112 funds tracked by Wall St. Rank hold BSTC as of Q4 2019.

  • Wedge Capital Management reported no remaining BioSpecifics Technologies Corp. position as of Q4 2019 after selling out during the quarter.
  • Wedge Capital Management sold 27,373 BioSpecifics Technologies Corp. shares in Q4 2019, an estimated $1.47M.
  • Wedge Capital Management first reported a position in BioSpecifics Technologies Corp. in Q1 2017 and held it in 3 quarters.
  • Wedge Capital Management's BioSpecifics Technologies Corp. position peaked at $2.09M in Q1 2017.
  • 112 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2019.

Based on Wedge Capital Management's 13F filing for Q4 2019, filed 15 Jan 2020.